National Academies Press: OpenBook

The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science (2011)

Chapter: Appendix B: Summary of a Meeting of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Held May 2425, 2010, Moscow, Russian Federation

« Previous: Appendix A: Agenda
Suggested Citation:"Appendix B: Summary of a Meeting of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Held May 2425, 2010, Moscow, Russian Federation." Institute of Medicine. 2011. The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science. Washington, DC: The National Academies Press. doi: 10.17226/13033.
×

Appendix B


Summary of a Meeting of the National
Institute of Allergy and Infectious
Diseases, National Institutes of
Health, Held May 24–25, 2010,
Moscow, Russian Federation

During the workshop, Barbara Laughon of the National Institute of Allergy and Infectious Diseases summarized a meeting on research opportunities in TB drug discovery and diagnostics held on the 2 days before the workshop. The goals of that meeting, said Laughon, were to exchange information among researchers from the United States, Europe, Russia, China, and other countries and explore opportunities for collaborative research. Laughon focused in particular on how to increase cooperation among countries. The following are highlights of the discussions at the meeting:

  • Russian Federation scientists are highly active in important areas of TB research, and multiple institutions are engaged in drug discovery, diagnostic, immunological, and pathological studies on TB.
  • Sophisticated molecular diagnostics for MDR TB have been developed. However, these diagnostics are not necessarily available at the point of care.
  • MDR and XDR TB strains are highly prevalent in Russia, but drug susceptibility testing for second-line drugs, as in the rest of the world, has yet to be standardized.
  • Improved sensitivity of TB detection in HIV-positive individuals is needed.
  • Differentiating between non-TB mycobacteria and Mycobacterium tuberculosis at the point of care can be difficult, leading in some cases to inappropriate treatment.
Suggested Citation:"Appendix B: Summary of a Meeting of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Held May 2425, 2010, Moscow, Russian Federation." Institute of Medicine. 2011. The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science. Washington, DC: The National Academies Press. doi: 10.17226/13033.
×
  • Diagnostics and treatment regimens formulated for pediatric TB patients generally are not available.
  • Support for basic science contributing to drug discovery is lacking. Improved connections among medicinal chemists, microbiological laboratories, and clinical investigators could hasten drug discovery.
  • Facilities for the biosafety level-3 laboratories needed for some MDR TB research in Russia are limited.
  • The TB strains used as standards in the West differ somewhat from those used as standards in Russia. These differences should be considered in comparing results of tests of diagnostics and drug effectiveness.
  • Diagnostic drug susceptibility testing needs to be harmonized across Russia and, in particular, with new drug developers.
  • Increased communication and collaboration among investigators within and outside of Russia could be beneficial to all participants. For example, the importation of reagents, equipment, and microbes is currently a barrier to collaborative research.
  • Research opportunities supported by the National Institutes of Health and other organizations are open to Russian investigators.
  • The clinical trial infrastructure needs to be strengthened for registration studies.
  • Regulatory and bureaucratic bottlenecks need to be removed for chemical entities in Phase I and Phase II clinical trials.
  • Standards of care and approaches to TB treatment need to be harmonized for multicenter trials.
  • Present clinical sites in Russia and other nations need to be sustained and supported for forthcoming global Phase III trials.
Suggested Citation:"Appendix B: Summary of a Meeting of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Held May 2425, 2010, Moscow, Russian Federation." Institute of Medicine. 2011. The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science. Washington, DC: The National Academies Press. doi: 10.17226/13033.
×
Page 121
Suggested Citation:"Appendix B: Summary of a Meeting of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Held May 2425, 2010, Moscow, Russian Federation." Institute of Medicine. 2011. The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science. Washington, DC: The National Academies Press. doi: 10.17226/13033.
×
Page 122
Next: Appendix C: Participant Biographies »
The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop by the Institute of Medicine and the Russian Academy of Medical Science Get This Book
×
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

An estimated 2 billion people, one third of the global population, are infected with Mycobacterium tuberculosis, the bacterium that causes tuberculosis. Spread through the air, this infectious disease killed 1.7 million in 2009, and is the leading killer of people with HIV. Tuberculosis (TB) is also a disease of poverty--the vast majority of tuberculosis deaths occur in the developing world. Exacerbating the devastation caused by TB is the growing threat of drug-resistant forms of the disease in many parts of the world.

Drug-resistant tuberculosis presents a number of significant challenges in terms of controlling its spread, diagnosing patients quickly and accurately, and using drugs to treat patients effectively. In Russia in recent decades, the rise of these strains of TB, resistant to standard antibiotic treatment, has been exacerbated by the occurrence of social, political, and economic upheavals. The Institute of Medicine (IOM) Forum on Drug Discovery, Development, and Translation, in conjunction with the Russian Academy of Medical Sciences held a workshop to discuss ways to fight the growing threat of drug-resistant TB. The New Profile of Drug-Resistant Tuberculosis in Russia: A Global and Local Perspective: Summary of a Joint Workshop presents information from experts on the nature of this threat and how it can be addressed by exploring various treatment and diagnostic options.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!